Microgravity Research Applications

Have you studied the fluid dynamics at school? Inside the ISS, 250 miles above the earth, the Soft Cell experiment shows what happens when one fundamental force disappears: gravity. And when gravity turns off, fluids reveal behaviors we never see on Earth: - Water becomes perfect spheres - No convection — patterns appear with mathematical purity - Mixing slows to near-zero, enabling precision at the atomic scale - Interfaces behave like living sculptures Microgravity becomes the cleanest physics lab in existence. Why it matters (real impact): + 20× more ordered protein crystals → better drug design + 10–100× more uniform materials → higher-performance semiconductors & alloys + More accurate rocket fuel slosh models → safer launches + Improved climate and turbulence simulations + Better life-support and water recovery systems for spaceflight This isn’t sci-fi — it’s industry-changing science happening right now. The Soft Cell proves one thing: ✨ Sometimes nature shows its most elegant physics only when we leave Earth behind. #SpaceTech via @oxford.mathematics #FluidDynamics #Innovation #Physics #ISS #Engineering #AdvancedMaterials #PharmaInnovation #Aerospace #DeepTech #Research #FutureOfScience

Cancer cells proliferate much more quickly in microgravity. Pr. Chunhui Xu from Emory University considered that if cardiac cells respond to microgravity in the same way cancer cells do, space-based research could hold the key to accelerating the development of cell-based regenerative therapies for heart disease. She said that research on the ISS could allow to develop a new strategy to generate cardiac cells more efficiently with improved survival when transplanted into damaged heart tissue. Her project EAGLE (engineering heart aggregates by leveraging microgravity)—launched on Space X Crew-8 mission. When the live cells were returned to Earth, Xu and her team found the cells had survived the trip, showing that functioning heart muscle cells could be generated in space. Microgravity increased gene expression involved in cardiac cell development and proliferation. Xu said: ‘Metabolic pathways that we have seen in the proliferation and survival of cancer cells were also activated in the cardiac cells in space,” Such space-based research could lead to significant advances in the Earth-based production of cardiac cells for regenerative therapies to treat heart disease. Image: Cardiac microtissues (spheroids). Parvin Forghani, Cardiomyocyte Stem Cell Laboratory

In microgravity, liquids behave in ways that challenge nearly all Earth-based engineering assumptions. Without gravity pulling fluids downward, water and fuel float freely, form spheres, and cling unpredictably to surfaces. To address this, engineers are developing containers that rely on surface tension — not gravity — to store and move liquids in space. These systems use carefully shaped geometries, capillary channels, and material properties to guide fluids passively. No pumps, no spinning tanks — just physics embedded in design. Several of these concepts are now being tested in orbit. What this unlocks: 💧 Reliable life-support systems, from drinking water to medical fluids 🚀 More efficient propellant management with fewer moving parts 🧪 New microfluidic capabilities for biotech, pharmaceuticals, and materials research in orbit As missions extend farther and longer, surface-tension–driven fluid management may become a foundational technology for spacecraft systems — simpler, lighter, and more robust than many traditional approaches. Curious how these designs will shape the next generation of space hardware. #Space #SpaceEngineering #Microgravity #Fluids #Liquids #SurfaceTension #AerospaceInnovation #SpaceExploration #Futures #ISS #Engineering #SpaceResearch #InOrbitManufacturing #PropellantManagement #SpaceHabitation #DeepSpaceMissions

LIGHT-DRIVEN PROPULSION OF GRAPHENE AEROGELS IN MICROGRAVITY Understanding how ultralight materials respond to light under reduced gravity is essential for developing future propellant‑free spacecraft technologies. Microgravity—achieved naturally in orbit or artificially during parabolic flights—provides a unique environment where weight and normal‑force friction are effectively removed, allowing subtle photothermal forces to dominate. During a parabolic flight, an aircraft follows repeated steep arcs, producing ~20‑second windows of near‑weightlessness with residual accelerations as low as 10⁻²–10⁻³ g. These conditions enable precise measurements of light‑induced motion that are otherwise masked on the ground. Graphene aerogels are ideal candidates for such studies. Built from a 3D network of graphene sheets, they combine extreme lightness (densities as low as 0.00016 g/cm³), high porosity, mechanical resilience, and strong thermal responsiveness. Their parent material—single‑layer graphene—exhibits exceptional thermal conductivity (up to 5000 W/mK), high stiffness (Young’s modulus ~1 TPa), and remarkable tensile strength. These properties make graphene aerogels uniquely suited for converting absorbed light into mechanical work. Over the past decade, researchers have uncovered a spectrum of light‑driven behaviors in graphene and related materials: ion‑trap levitation, magnetic‑field‑modulated motion, bulk propulsion of graphene sponges, radiometric forces, Knudsen pumping, and nanoscale bubble actuation. Together, these studies established that graphene can translate, rotate, or accelerate when illuminated—through mechanisms ranging from angular momentum transfer to photothermal gas‑flow forces. Recent experiments used 10 × 10 × 5 mm aerogel samples (density ~0.01 g/cm³) placed in a vacuum chamber (~10⁻⁴ mbar) and illuminated with a 532 nm, 5 W laser. High‑speed imaging captured their motion across gravitational regimes. In microgravity, the aerogels exhibited rapid, strong propulsion: 50 mm displacement in 0.05 s Peak velocity ~1.7 m/s Accelerations >100 m/s² Initial thrust pulse ~0.6 mN within 30 ms Under 1 g, the same samples showed strongly suppressed motion: ~15 mm displacement at ~0.16 s ~0.06 m/s peak velocity ~11 µN thrust Removing gravitational load reveals the full magnitude of optically induced forces in these ultralow‑density networks. The results also show that propulsion depends non‑monotonically on aerogel density, with intermediate architectures producing the strongest thrust. By directly comparing distance, velocity, and transient thrust across microgravity and ground conditions, this study establishes the first quantitative benchmarks for light‑driven propulsion in reduced gravity. These findings support future concepts in propellant‑free spacecraft technologies, laser‑driven micro‑thrusters, attitude‑control systems for small satellites, and ultralight graphene‑based solar sails. # https://lnkd.in/eNta253X

An international research team boarded ESA’s 86th parabolic flight campaign in May 2025 with ultralight graphene aerogels, then hit them with light during zero gravity phases to observe their reaction under space-like conditions. The effect of the laser during the microgravity phases was startling: the graphene samples shot forward instantly. Inside a vacuum chamber, a continuous laser beamed on three small cubes made of graphene aerogel. A high-speed camera recorded the action through glass tubes. Graphene aerogels are ultralight, highly porous materials that merge graphene’s exceptional electrical conductivity with the structural advantages of aerogel architecture. They maintain strong mechanical performance despite their low density. “The reaction was fast and furious. Before you could even begin to blink, the graphene aerogels experienced large accelerations. It was all over in 30 milliseconds,” explains Marco Braibanti, ESA’s project scientist for the experiment Light‑driven propulsion of graphene aerogels in microgravity. Researchers at the Université Libre de Bruxelles (ULB) in Belgium and Khalifa University in the United Arab Emirates (UAE) led the study. Under Earth’s gravity conditions, the aerogels barely moved at all. The results, published in Advanced Science, demonstrate that microgravity unlocks the potential of light propulsion for graphene aerogels in terms of velocity, thrust and distance. Another finding was the ability to control the propulsion by tuning the light beam. “The stronger the laser, the greater the acceleration. The laser pulse triggers a sharp acceleration peak, after which the aerogels slow down,” adds Marco. Although still fundamental science, these promising results show that using light to propel graphene aerogels in space is not only possible, but remarkably efficient. Future space technologies with built-in graphene might include solar sail propulsion and attitude-control for small satellites. Next-generation aerogels could convert light into motion, saving fuel critical for the duration of a space mission and allowing more room for other technologies. “We are opening the path to a propellant-free propulsion future. Ultralight graphene aerogels are the perfect example of an innovative material created in the lab that could save us large amounts of fuel and hardware in space,” says Ugo Lafont, ESA’s materials’ physics and chemistry engineer. Previous research into the interaction of light with graphene has revealed a wide spectrum of motion, ranging from levitation and rotation to bulk and nanoscale propulsion. ESA is currently exploring this potential through the Enable topical team, a working group which is also assessing the full range of benefits related to 2D materials. #ESA #Propulsion #Microgravity Light hits graphene aerogel. (ESA)

On Earth, flames rise because hot gases are lighter than the surrounding air. In space, however, there's no buoyancy. That's why fire takes on a beautiful, pulsating jellyfish-like shape. The Flame Extinguishment - 2 (FLEX-2) experiment aboard the International Space Station investigates how small droplets of fuel burn in microgravity. By studying these perfectly spherical flames, researchers can understand how fuel evaporates, burns, and produces soot without the interference of gravity. This allows them to measure the burning rate, flame temperature, and smoke formation with unmatched precision. The results helped improve both space travel and Earth-based energy systems. In orbit, this knowledge helps design safer spacecraft by reducing fire hazards and improving the efficiency of onboard fuel mixtures. On Earth, it guides the creation of cleaner, more efficient fuels that burn completely and produce less ashes or smoke. It is a critical factor for environmental health and next-generation engine design.

How Microgravity is Revolutionizing Healthcare Research and Development Microgravity is opening a new era for medical research, offering scientists insights they cannot obtain on Earth. In weightlessness, biology behaves differently. Proteins crystallize with greater clarity, allowing more precise drug design. Stem cells expand in new ways, revealing possibilities for regenerative medicine. Even fragile cell models survive longer in orbit, giving researchers extended time to study diseases like cancer. Angiex Inc. offers a clear example. Its therapy targets the blood vessels that feed tumors. On Earth, endothelial cells rarely live long enough for meaningful testing. In orbit, they thrived, giving researchers a stable platform to explore how cancers can be deprived of their lifelines. This unique environment is why leading research centers are heading to space. UC San Diego scientists are testing cancer drugs aboard the International Space Station, while Cedars-Sinai is growing human tissues in orbit. Harvard and Massachusetts General Hospital study how the body adapts under space-like conditions, revealing potential treatments for aging and chronic illness. Startups are equally active in utilizing microgravity. Varda Space Industries has raised $187 million to expand its space-based drug crystallization platform. Frontier Space, recently completed its first orbital mission with ATMOS Space Cargo, validating key technologies aboard its SpaceLab Mark 1 research platform. Launched on 21 April 2025 aboard SpaceX’s Bandwagon-3 and hosted in ATMOS’s Phoenix capsule, the mission confirmed the readiness of its systems for research and manufacturing in orbit. The emerging New Space sector is proving that orbital healthcare research represents not only scientific opportunity but a compelling business case. By providing the ability to conduct experiments in microgravity and return materials to Earth, these companies are demonstrating that space-based research can be both economically sustainable and transformative for Earth-based medicine. From more effective cancer treatments to advanced tissue engineering, the therapies developed in orbit promise to address some of humanity's most important health challenges—showing that the New Space can deliver tangible benefits that improve lives.   #SpaceMedicine #MicrogravityInnovation #SpaceHealthcare #NewSpace   Image credit: Aurich Lawson Article Draft by Leslei Makori

Drug development in space is a big deal! Florida-based Redwire Space (NYSE: RDW), a space infrastructure company, has just announced the first spaceflight mission for its cutting-edge in-space pharmaceutical manufacturing platform, PIL-BOX. This first mission sends Eli Lilly and Company’s materials to space to conduct three critical experiments in microgravity, focused on developing advanced treatments for diabetes, cardiovascular disease, and pain. Understanding crystal growth and design can inform the entire drug development and design process as pharmaceutical companies look to deliver new, optimized treatments to help patients on Earth. Previous spaceflight investigations indicate that growing crystals in the microgravity of space could yield a more uniform product with fewer imperfections. The new platform by Redwire will launch onboard SpaceX’s 29th cargo resupply services mission (SpaceX-29) for NASA to the International Space Station (ISS). Back in March, Bristol Myers Squibb embarked on its second mission to research protein crystallization in microgravity aboard the ISS, aiming to develop more stable and concentrated biologic medicines that could lead to simpler, at-home patient treatments. BMS experiment was launched as part of SpaceX's 27th commercial resupply mission to the ISS. Also, Merck has been working on crystalline suspensions of monoclonal antibodies, like those in Keytruda, their oncology drug, finding that crystals grown in space have lower viscosity and better injectability properties. This could transform the drug delivery method from lengthy infusions to quick injections. Protein crystallization is not the only interest of life science companies in space. On SpaceX-29, Redwire is also launching materials for an investigation that will bioprint cardiac tissue on orbit using Redwire’s BioFabrication Facility (BFF). This type of technology could be used to develop heart patches that can be applied to the outside of damaged hearts and advance our ability to print complex, thick tissues that cannot be produced on Earth. In September, Redwire announced that it had successfully 3D-bioprinted the first human knee meniscus on orbit using BFF. The print was returned to Earth for further study and analysis. #biopharmatrend #deeptech #spaceindustry #biotech Image credit: NASA

What does space have to do with cancer drugs? It's more than you think. Here’s what changed in 2024–25: 👉UC San Diego & Sanford Stem Cell Institute sent tumor organoids and stem cells to the ISS. 👉Axiom Space carried Rebecsinib (ADAR1 inhibitor) for tumor response studies with Aspera Biomedicines & UCSD. 👉BioOrbit and Varda Space Industries started working on orbital manufacturing of biologics like monoclonal antibodies. 👉Redwire Space built hardware to support space-based oncology research. Why does space matter for drug development? 📍Microgravity grows bigger, purer protein crystals → sharper drug targets. 📍Tumor organoids & stem cells behave differently → reveals cancer mechanisms we can’t easily see on Earth. 📍Space capsules can test and formulate high-value biologics in low volume. But this interesting concept has its challenges: ➜ FDA & regulatory standards apply the same as Earth-made drugs. ➜ Multiple flights needed to prove reproducibility. ➜ Radiation in orbit may alter biological models. ➜Launch costs are still high. 📍Key people & organizations shaping this field: ☆ Academic: Dr. Catriona Jamieson, Sanford Stem Cell Institute, UC San Diego ☆ Biomedicines, BioOrbit, Varda, Redwire ☆ Government: NASA, ISS National Lab ☆ Commercial: Axiom Space, Aspera For the first time, oncology research has real preclinical pipelines in orbit. This could accelerate: ✔️Better structural data for drug design ✔️Faster preclinical insights from organoids ✔️New biologics designed and manufactured in space One thing is clear: space is no longer sci-fi for oncology. It’s a lab. A factory. A new partner in drug development. P.S.- Would you trust a cancer drug first designed with data from space?

AI is supposed to fix pharma's productivity crisis. It won't; at least not on its own. Gravity is a variable, too, and we can finally properly access microgravity 250 miles up. ~90% of clinical candidates still fail, largely because preclinical models on Earth don't predict human outcomes well enough. Cells in cultures sediment under gravity and grow as 2D rather than 3D, so they don't behave as they would in a body. In microgravity (µG), they grow in 3D, not perfectly, but much closer to how they grow in us. AI can't fix this yet. It's data-limited, and orbit is a great place to generate what we need to model human biology better. Every experiment in human history on Earth has had a 1G field. In microgravity, a few things change: - No buoyancy or sedimentation: on Earth, denser stuff sinks, lighter stuff floats. In µG, mixtures disperse more evenly, yielding greater uniformity in, e.g., alloys and crystals. - No convection: heat a fluid on Earth and warm liquid rises while cool falls. That loop jostles whatever's forming, disrupting crystal lattices and layered deposition. In µG, formation happens undisturbed. - No hydrostatic pressure: a fluid's weight presses on what's below it, distorting deposition and limiting precision. In µG, that's negligible, allowing precision placement at scales Earth struggles with. - No container requirement: on Earth, liquids need containers or they spread, which means contact, contamination, geometric limits. In µG, they hold themselves as free-standing droplets. Big deal for 3D biomanufacturing where scaffolding constrains tissue geometry. In practice, this translates into two kinds of work in LEO: - Research: use µG to find signals we can't get at 1G, then bring findings back. Merck leveraged μm-grown crystals on the ISS to reformulate Keytruda (~$30B rev/year) from a lengthy IV infusion into a subcutaneous injection. Encapsulate showed metastatic tumor cells have higher motility in space vs non-invasive ones. Gravity masks this on ground, where all move at the same rate. µG also triggers aging-like changes (bone loss, cardiovascular, immune decline) in weeks, useful for modeling diseases that take decades on Earth. - Manufacturing: products made in orbit. LambdaVision, Inc. makes 200-layer protein-based artificial retinas in space. At 1G, imperfections compound across cycles; in µG, no compounding thanks to the lack of sedimentation/convection. Varda Space Industries crystallizes small-molecule active pharmaceutical ingredients (APIs) in orbit. Space is really just another lab with a slightly different environment. So, back to our beloved AI. Some training data for models of human biology is easier to generate in orbit than on Earth: cells in 3D, certain crystal structures, disease phenotypes that take decades to show on Earth but weeks in space. µG gets further on specific things. The more research done up there, the more data for AI to learn from. #space #pharma #biomanufacturing